Skip to Content

Join the 'Letairis' group to help and get support from people like you.

Letairis News

Impotence Drug Aids Treatment of Rare Lung Disease: Study

Posted 26 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 26, 2015 – A combination treatment using the erectile dysfunction drug Cialis may greatly reduce death and hospitalization from an incurable lung disease that mainly affects women, a new clinical trial shows. Cialis combined with a blood pressure medication called ambrisentan (Letairis) significantly reduced the progression of pulmonary arterial hypertension, according to results published in the Aug. 27 issue of the New England Journal of Medicine. The condition involves high blood pressure in the arteries leading into the lungs. People who took the combination therapy were half as likely to die, require hospitalization or have severe progression of their illness, when compared with people who only received one of the two drugs, researchers found. The results are so encouraging that the maker of Cialis, GlaxoSmithKline, has submitted them to the U.S. Food and Drug ... Read more

Related support groups: Cialis, Pulmonary Hypertension, Tadalafil, Adcirca, Letairis, Respiratory Failure, Ambrisentan

Accidental Medication Poisonings in Kids on the Rise

Posted 16 Sep 2011 by Drugs.com

FRIDAY, Sept. 16 – Despite ongoing prevention efforts, a growing number of young children are being accidentally poisoned with medications, according to new research. The study, which was based on data reported to the American Association of Poison Control Centers between 2001 and 2008, found that medication poisoning among children aged 5 and under increased by 22 percent, although the number of children in the United States in this age group rose by only 8 percent during the study period. "The problem of pediatric poisoning in the U.S. is getting worse, not better," Dr. Randall Bond, of Cincinnati Children's Hospital Medical Center, said in a hospital news release. In conducting the study, which is scheduled for publication in the Journal of Pediatrics, the researchers reviewed information on over 544,000 children who landed in the emergency department due to medication poisoning ... Read more

Related support groups: Xanax, Suboxone, Oxycodone, Hydrocodone, Methadone, Percocet, OxyContin, Klonopin, Vicodin, Lisinopril, Norco, Fentanyl, Clonazepam, Morphine, Ativan, Ambien, Valium, Codeine, Metoprolol, Lortab

FDA Drug Safety Communication: Liver Injury Warning to be Removed from Letairis (ambrisentan) Tablets

Posted 8 Mar 2011 by Drugs.com

Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data Summary Safety Announcement [03-04-2011] The U.S. Food and Drug Administration (FDA) is removing the warning related to liver injury from the boxed warning of the Letairis (ambrisentan) tablet label. Further evaluation of the clinical trial data and post-marketing safety information has led the FDA to conclude that the risk of liver injury in patients treated with this drug is low. FDA has also concluded that routine monthly serum liver enzyme testing for patients taking Letairis is not necessary.  Healthcare professionals should still continue to order liver enzyme tests when they consider it clinically necessary. The boxed warning on the risk of serious birth defects and the contraindication for use during pregnancy will remain in the Letairis label.  Monthly pregnancy t ... Read more

Related support groups: Letairis, Ambrisentan

U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis

Posted 8 Mar 2011 by Drugs.com

-- Monthly Liver Function Monitoring No Longer Required – FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 4, 2011 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a change to the prescribing information for Letairis® (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms. This change removes language concerning the potential risk of liver injury from the Boxed Warning. In conjunction with this label update, PAH patients receiving Letairis are no longer required to obtain monthly liver function tests. The FDA approved the new labeling based on its review of post-marketing data reflecting use of Letairis over more than 7,800 patient y ... Read more

Related support groups: Letairis, Ambrisentan

Ask a Question

Further Information

Related Condition Support Groups

Pulmonary Hypertension

Letairis Patient Information at Drugs.com